Nuclear factor kappa-light-chain-enhancer of activated B cells pathway regulatory proteins (NF-κB)

Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) pathway regulatory proteins are a complex network of signaling molecules and transcription factors that serve as master regulators of the immune and inflammatory response (NIH, 2024; Wikipedia, 2024). The pathway is centered around the NF-κB transcription factor family, which is typically held in an inactive state in the cytoplasm by Inhibitor of κB (IκB) proteins (NIH, 2024; Abcam, 2024). Upon activation by various stimuli, including pro-inflammatory cytokines and pathogens, the IκB kinase (IKK) complex phosphorylates IκB, triggering its ubiquitination and subsequent degradation by the proteasome (NIH, 2024). This release allows NF-κB dimers to translocate into the nucleus and initiate the transcription of genes involved in cell survival, proliferation, and the production of inflammatory mediators (AnyGenes, 2024; NIH, 2024). Dysregulation of these regulatory proteins is a key driver in the pathogenesis of numerous diseases, including chronic inflammatory conditions, autoimmune disorders, and various malignancies (NIH, 2024). In cancer, constitutive NF-κB activity promotes tumor cell survival, angiogenesis, and resistance to chemotherapy (NIH, 2024). Therapeutic strategies targeting this pathway include proteasome inhibitors like bortezomib, specific IKK inhibitors, and biological agents that neutralize upstream activators like TNF-α (NIH, 2024). While effective, targeting these proteins presents significant challenges, including the risk of systemic immunosuppression and potential toxicity due to their broad physiological roles (NIH, 2024). Monitoring pathway activity often involves assessing the nuclear translocation of NF-κB subunits or the levels of downstream inflammatory biomarkers (NIH, 2024). Overall, these proteins represent a high-value but complex target space for drug development in oncology and immunology (ResearchGate, 2024; NIH, 2024).

Other names

NF-kappaBNF-kBNuclear factor-kappa BIkappaB kinase complexIKK complexInhibitor of kappa B proteinsIκB proteins

Drugs targeting the NF-κB pathway regulatory proteins act by inhibiting the IκB kinase (IKK) complex, blocking the proteasomal degradation of IκB inhibitory proteins, preventing the nuclear translocation of NF-κB dimers, or antagonizing upstream activating receptors such as TNFR and IL-1R.